An estimated 35% of people living with cystic fibrosis (CF) – including both children and adults – are unaware that they have the condition. Failure to detect CF at newborn screening may lead to diagnostic delays persisting as long as into adulthood. Missed or delayed diagnoses of CF and CFTR-related disorders can have important implications for disease progression and health outcomes. Participants in this program will increase their awareness about missed diagnoses of CF, examine factors that lead to missed diagnoses including race, rare mutations and pancreatic sufficiency, and analyze options for patient testing and treatment of suspected CF and CFTR-related disorders. This online program is led by Dr. Jennifer Taylor-Cousar, MD, MSCS, ATSF; Dr. Jared J. Eddy, MD, MPhil, MSc; and Sara Dederman Brayshaw, RN, BS, MSN. Target Audience: Infectious Disease Physicians, Pulmonologists, Gastroenterologists, Primary Care Physicians, advanced practice providers and registered nurses. 1.0 CME/CNE https://brnw.ch/21wKRUw
National Jewish Health’s Post
More Relevant Posts
-
Controlling migraine disease in adolescents before they transition into adulthood is imperative to prevent long-term negative consequences and improve their quality of life. Learn how to address the unique needs of the adolescent population with a new Continuing Medical Education (CME) course “Unmet Needs in Treating Adolescent Migraine.” Led by esteemed US pediatric neurologist and headache specialist Dr. Shannon Babineau, this one-hour session offers valuable insights into the disease state, specifically addressing the unmet needs of young patients, and exploring the latest available therapies. It presents an invaluable opportunity to learn how to safely and effectively treat the 100 million adolescents with migraine disease. Participating providers will also earn 1.0 ACCME credit. Access the course here: https://lnkd.in/d5EXyXNS ___________________________________________ Disclosure: this CME session was made possible through an educational grant by Theranica. Nerivio® is a neuromodulation device indicated for the acute and/or preventive treatment of migraine with or without aura in patients from the age of 12 years. Nerivio can be obtained with a medical prescription. As with any therapy, there may be side effects and contraindications. Not all patients respond to the therapy in the same way, meaning that treatment results can vary individually. Consult your physician in case of any questions. Information on indications and contraindications, as well as instructions for use, can be found here: https://lnkd.in/erZ6mq6N
To view or add a comment, sign in
-
-
This #ResearchBreakdown is from Pai et al (2024) who looked at how health inequities may impact the incidence of paediatric stroke (or the number of individuals having the condition) and time from onset of symptoms to arrival at hospital. Read more here: https://lnkd.in/e8Vd-esB This study compared patients up to 18 years old that had been diagnosed with acute arterial ischaemic stroke, or a stroke caused by clot in an artery in the brain and compared their neighbourhoods and the resources available to those areas. Patients were also broken into groups dependent on the time between stroke symptom onset and arrival to A&E, which in the entire population occurred within 24 hours. Researchers found that areas with fewer resources (higher resource deprivation) had higher rates of paediatric stroke, which has been seen in other conditions. It’s well-established in research that areas with fewer resources tend to have higher rates of disease and infection. Interestingly, researchers also found that the time between onset and arrival at hospital was decreased in these same neighbourhoods. While they had higher rates of paediatric stroke, they were more likely to be faster at seeking assistance. This study opens the door for interesting research into understanding why time for medical assistance was decreased in areas with higher rates of paediatric stroke but fewer resources.
To view or add a comment, sign in
-
Chief Executive Officer at JobRx | Top 1% Industry SSI rank on LinkedIn | Top 1% Network SSI rank on LinkedIn
APhA collaborates with CDC to advance health equity and prevent heart disease and stroke To further the implementation of pharmacy-based efforts to promote health equity and prevent heart disease and stroke, APhA has entered into a contracted project agreement with CDC's Applied Research and Evaluation Branch in the Division for Heart Disease and Stroke Prevention. Cardiovascular disease — the leading cause of death in the United States — is affected by health equity-related factors, including socioeconomic status, environmental conditions, institutional factors, structural racism, and various forms of discrimination. A key objective of the new project is to create solutions that work to prevent heart disease and stroke in all communities. "Pharmacists are trusted community health professionals who are highly accessible to patients and who increasingly engage in team-based care in practice settings that historically work with medically underserved patients," said Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, executive vice president and CEO of APhA. "This project will build on the trust that people already have in their pharmacists to provide health screenings, education, and medication adherence counseling as they thoughtfully and comprehensively address patient concerns. Pharmacists, working together with public health entities, are a crucial partner in reducing the risk of heart disease and stroke in the United States." APhA's goal is "to inspire, innovate, and create opportunities for its members and pharmacists worldwide to optimize medication use and health for all," which dovetails with CDC's aim to boost cardiovascular health equity. Steps APhA will take to further this goal include convening a community of practice to provide innovative peer-to-peer learning and capacity-building opportunities for health departments and pharmacy partners; identifying and tailoring promising program models to meet community needs, overcoming challenges to implementation, building capacity for evaluation and dissemination; and contributing to practice-based evidence for pharmacy-based strategies to advance health equity in heart disease prevention and treatment. ttps://buff.ly/3RSIMpj
To view or add a comment, sign in
-
-
Background: Children generally are less contaminated by COVID-19 than other age groups, but multisystem inflammatory syndrome-children (MIS-C) can cause severe outcomes in some children. The information about MIS-C patient mortality is limited, and the cause of mortality may vary by geographical region. Therefore, we performed this case series study to report the clinical features and treatment of MIS-C patients associated with COVID-19 who died in selected referral hospitals in Iran. Case Presentation: We presented 9 cases of deceased MIS-C patients hospitalized from March 2020 to September 2021. The median age of deceased patients was 89 months (interquartile range: 8-162 mo). Five patients (55%) were male. The COVID-19 reverse transcription polymerase chain reaction (PCR) or serology test was positive in 7 children (77%). About 80% of the patients had comorbidities, most commonly obesity. All the patients were febrile at admission, and 77.78% had a fever for over 5 days. Respiratory, cardiac, and gastrointestinal signs were the most common. On admission, 6 patients were transferred to the pediatric intensive care unit. All patients received intravenous immunoglobulin and steroids. Conclusions: The most common organ failure was lung, heart, liver, and kidney, but the main cause of death was cardiopulmonary failure. Early diagnosis and management of MIS-C are necessary to prevent severe complications and death. #Mortality, #Multisysteminflammatorysyndrome, #Child, #COVID19, #Iran
To view or add a comment, sign in
-
Association between blood pressure recording in prehospital setting and patient outcome in pediatric trauma patients: A propensity score matching study RESULTS During the study period, 13,413 pediatric patients were included. There were 9,187 and 1,798 patients with and without prehospital blood pressure records, respectively. After matching, there were no differences in the patient characteristics or disease severity. Hospital mortality was significantly higher in the nonrecorded group than in the recorded group (4.3% vs. 1.1%; p < 0.001). The multiple logistic regression analysis results showed no prehospital record of blood pressure being associated with death (odds ratio [OR], 6.82; 95% confidence interval [CI], 2.40–19.33). Glasgow Coma Scale score and Injury Severity Score were also associated with death (OR, 0.71; 95% CI, 0.63–0.81 and OR, 1.10; 95% CI, 1.06–11.14, respectively). https://lnkd.in/gbuz_CBh
To view or add a comment, sign in
-
-
This article discusses bronchopulmonary dysplasia (BPD), a chronic lung condition that primarily affects preterm infants, especially those with very low birth weight. Despite advances in the treatment and prevention of respiratory problems associated with prematurity, the incidence of BPD has not decreased significantly, posing ongoing challenges in neonatal care. The article critically reviews the diagnostic criteria for BPD, highlighting the importance of uniform clinical diagnosis and reducing intercenter variability. It focuses on the evolution of the disease, its severity and the differences in its clinical presentation over time. In addition, it addresses the need for a standardized approach to the definition and classification of BPD, which is crucial for the implementation of effective treatment strategies and prognostic assessment. This study underscores the need for continued innovation and adaptation in the methods of diagnosis and treatment of BPD, reflecting how progress in neonatal care and ventilation techniques may influence the presentation and management of this complex disease. The importance of accurate diagnosis and appropriate management of BPD is critical, not only to improve immediate outcomes in neonates, but also to minimize long-term impacts on their respiratory health.
To view or add a comment, sign in
-
The primary endpoint of this study was mortality at 6 months. Which showed no significant difference between TXA and Placebo, however, secondary endpoints of 24hrs and 28 day survival rates showed that 9.7% of patients in the tranexamic acid group and 14.1% of patients in the placebo group had died at the 24 hour marker and 17.3% of patients in the tranexamic acid group and 21.8% of patients in the placebo group had died at the 28 day marker. The risk ratios of 24hr and 28 day death are 0.69 and 0.79 respectively. This indicates that mortality of severely injured trauma patients can be reduced by nearly 75% within these shorter timeframes. Taking TXA's primary function is to prevent the breakdown of blood clots that are already formed at face value, it is clear that the patient's in an acute setting were less likely to die from massive hemorrhage. https://lnkd.in/eVN8J2Wb
Prehospital Tranexamic Acid for Severe Trauma | NEJM
nejm.org
To view or add a comment, sign in
-
𝗦𝗵𝗼𝘂𝗹𝗱 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆 𝘀𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝘁𝘆𝗽𝗲 𝟭 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗯𝗲𝗰𝗼𝗺𝗲 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝗮𝗹𝗹 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻? New insights Science Magazine 👇 EDENT1FI seeks to halt early-stage type 1 diabetes across Europe, building on knowledge from e.g. #Fr1daStudy 👉 Read how #HelmholtzMunich contributes https://lnkd.in/eEygqu-d #type1diabetes #T1D
Check out the latest article in Science Magazine discussing the question: "Should doctors screen all kids for type 1 diabetes?" Recent studies suggest early detection could prevent severe complications. Cited experts like Chantal Mathieu, Rachel Besser, Emanuele Bosi, and Jurgen Vercauteren weigh in on the debate. Mass screenings show promise in reducing risks like diabetic ketoacidosis. With treatments like teplizumab delaying disease onset, the case for screening strengthens. However, psychological impact and logistical challenges remain concerns. Projects like EDENT1FI aim to address these issues. The decision on mass screening is complex, with implications for public health and individual well-being. Read more in Science Magazine: https://lnkd.in/edsduzDv
Should doctors screen all kids for type 1 diabetes?
science.org
To view or add a comment, sign in